Cargando…

External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD

BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Broese, Johanna M C, van der Kleij, Rianne M J J, Verschuur, Els M L, Kerstjens, Huib A M, Bronkhorst, Ewald M, Chavannes, Niels H, Engels, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792220/
https://www.ncbi.nlm.nih.gov/pubmed/36579356
http://dx.doi.org/10.2147/COPD.S387716
_version_ 1784859588004151296
author Broese, Johanna M C
van der Kleij, Rianne M J J
Verschuur, Els M L
Kerstjens, Huib A M
Bronkhorst, Ewald M
Chavannes, Niels H
Engels, Yvonne
author_facet Broese, Johanna M C
van der Kleij, Rianne M J J
Verschuur, Els M L
Kerstjens, Huib A M
Bronkhorst, Ewald M
Chavannes, Niels H
Engels, Yvonne
author_sort Broese, Johanna M C
collection PubMed
description BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be a promising tool for healthcare providers to identify patients with COPD who could benefit from palliative care. OBJECTIVE: To externally validate the ProPal-COPD tool and to assess user experiences. METHODS: Patients admitted with an acute exacerbation COPD were recruited across 10 hospitals. Demographics, clinical characteristics and survival status were collected. Sensitivity, specificity, positive and negative predictive values of the tool using two cut-off values were calculated. Also, predictive properties of the SQ were calculated. In monitoring meetings and interviews, healthcare providers shared their experiences with the tool. Transcripts were deductively coded using six user experience domains: Acceptability, Satisfaction, Credibility, Usability, User-reported adherence and Perceived impact. RESULTS: A total of 523 patients with COPD were included between May 2019 and August 2020, of whom 100 (19.1%) died within 12 months. The ProPal-COPD tool had an AUC of 0.68 and a low sensitivity (55%) and moderate specificity (74%) for predicting 1-year all-cause mortality. Using a lower cut-off value, sensitivity was higher (74%), but specificity lower (46%). Sensitivity and specificity of the SQ were 56% and 73%, respectively (AUC 0.65). However, healthcare providers generally appreciated using the tool because it increased awareness of the palliative phase and provided a shared understanding of prognosis, although they considered its outcome not always correct. CONCLUSION: The accuracy of the ProPal-COPD tool to predict 1-year mortality is limited, although screening patients with its indicators increases healthcare providers’ awareness of palliative care needs and encourages them to timely initiate appropriate care.
format Online
Article
Text
id pubmed-9792220
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97922202022-12-27 External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD Broese, Johanna M C van der Kleij, Rianne M J J Verschuur, Els M L Kerstjens, Huib A M Bronkhorst, Ewald M Chavannes, Niels H Engels, Yvonne Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be a promising tool for healthcare providers to identify patients with COPD who could benefit from palliative care. OBJECTIVE: To externally validate the ProPal-COPD tool and to assess user experiences. METHODS: Patients admitted with an acute exacerbation COPD were recruited across 10 hospitals. Demographics, clinical characteristics and survival status were collected. Sensitivity, specificity, positive and negative predictive values of the tool using two cut-off values were calculated. Also, predictive properties of the SQ were calculated. In monitoring meetings and interviews, healthcare providers shared their experiences with the tool. Transcripts were deductively coded using six user experience domains: Acceptability, Satisfaction, Credibility, Usability, User-reported adherence and Perceived impact. RESULTS: A total of 523 patients with COPD were included between May 2019 and August 2020, of whom 100 (19.1%) died within 12 months. The ProPal-COPD tool had an AUC of 0.68 and a low sensitivity (55%) and moderate specificity (74%) for predicting 1-year all-cause mortality. Using a lower cut-off value, sensitivity was higher (74%), but specificity lower (46%). Sensitivity and specificity of the SQ were 56% and 73%, respectively (AUC 0.65). However, healthcare providers generally appreciated using the tool because it increased awareness of the palliative phase and provided a shared understanding of prognosis, although they considered its outcome not always correct. CONCLUSION: The accuracy of the ProPal-COPD tool to predict 1-year mortality is limited, although screening patients with its indicators increases healthcare providers’ awareness of palliative care needs and encourages them to timely initiate appropriate care. Dove 2022-12-22 /pmc/articles/PMC9792220/ /pubmed/36579356 http://dx.doi.org/10.2147/COPD.S387716 Text en © 2022 Broese et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Broese, Johanna M C
van der Kleij, Rianne M J J
Verschuur, Els M L
Kerstjens, Huib A M
Bronkhorst, Ewald M
Chavannes, Niels H
Engels, Yvonne
External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title_full External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title_fullStr External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title_full_unstemmed External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title_short External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
title_sort external validation and user experiences of the propal-copd tool to identify the palliative phase in copd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792220/
https://www.ncbi.nlm.nih.gov/pubmed/36579356
http://dx.doi.org/10.2147/COPD.S387716
work_keys_str_mv AT broesejohannamc externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT vanderkleijriannemjj externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT verschuurelsml externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT kerstjenshuibam externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT bronkhorstewaldm externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT chavannesnielsh externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd
AT engelsyvonne externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd